This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
LLY to Buy Oncology Biotech Kelonia Therapeutics for $7 Billion
by Zacks Equity Research
Eli Lilly is set to acquire Kelonia Therapeutics in a $7B deal, boosting its genetic medicine platform with a novel in vivo CAR-T therapy for cancer.
LLYPositive Net Change ADMANegative Net Change
biotechnology biotechs cell-therapy gene-therapy medical oncology-screening pharmaceuticals
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
by Ekta Bagri
BMY stands out vs GILD, supported by a cheaper valuation, strong growth portfolio, and improving earnings outlook despite generic headwinds.
BMYPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca's Ultomiris Meets Goal in Rare Kidney Disease Study
by Zacks Equity Research
AZN's Ultomiris hits key goal in IgAN study, showing early proteinuria reduction as it eyes accelerated approval in major markets.
SNYNegative Net Change AZNNegative Net Change NVSPositive Net Change TVTXPositive Net Change
biotechs medical pharmaceuticals
Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD Study
by Zacks Equity Research
AGIO shares plunge after Novo Nordisk's strong sickle cell data raised doubts about mitapivat's competitiveness and approval prospects.
NVONegative Net Change AGIOPositive Net Change INDVPositive Net Change
biotechs medical
Viking Therapeutics Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
VKTX heads into Q1 earnings results with a focus on pipeline updates, as it expects no revenues and continued losses amid key obesity drug developments.
AGENPositive Net Change INONegative Net Change VKTXNegative Net Change
biotechs earnings medical
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in Q1?
by Ekta Bagri
BMY pivots to growth portfolio as legacy drugs decline, with rising new therapies helping offset revenue erosion and reshape the long-term outlook.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
by Ahan Chakraborty
Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.
SRPTPositive Net Change PTCTPositive Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
by Ahan Chakraborty
Keros reshaped its finances with a Takeda deal, boosting revenue and cutting R&D ??? but does it truly reduce dilution risk as 2026 uncertainty looms?
SRPTPositive Net Change PTCTPositive Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
KROS Rinvatercept: What to Know Before DMD Phase II Starts
by Ahan Chakraborty
KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward execution and high-stakes clinical catalysts.
SRPTPositive Net Change PTCTPositive Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
ANI Pharmaceuticals' 2026 Catalysts Include Gout Push and New Generics
by Sundeep Ganoria
ANIP eyes 2026 growth via Cortrophin's gout push and steady generics launches, as Rare Disease expansion reshapes priorities and investor focus.
REGNPositive Net Change ABBVPositive Net Change ANIPPositive Net Change
biotechs medical pharmaceuticals